COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,785 Articles (22,523 medRxiv, 8,262 bioRxiv)

Most recent first Previous |  Page 1218: Articles 12171-12180  | Next

An Extended Coatomer Binding Motif in the SARS-CoV-2 Spike Protein
Dey, D., Singh, S., Khan, S., Martin, M., Schnicker, N., Gakhar, L., Pierce, B., Hasan, S. S.
10.1101/2021.09.03.458953 — Posted: 2021-09-04
Network analysis outlines strengths and weaknesses of emerging SARS-CoV-2 Spike variants
Manrique, P. D., Chakraborty, S., Nguyen, K., Mansbach, R., Korber, B., Gnanakaran, S.
10.1101/2021.09.03.458946 — Posted: 2021-09-04
Genomic evidence for divergent co-infections of SARS-CoV-2 lineages
Zhou, H.-Y., Cheng, Y.-X., Xu, L., Li, J.-Y., Tao, C.-Y., Ji, C.-Y., Han, N., Yang, R., Li, Y., Wu, A.
10.1101/2021.09.03.458951 — Posted: 2021-09-04
Characteristics associated with COVID-19 vaccine uptake among adults in England (08 December to 17 May 2021)
Tessier, E., Rai, Y., Clarke, E., Lakhani, A., Tsang, C., Makwana, A., Heard, H., Rickeard, T., Lakhani, S., Roy, P., Edelstein, M., Ramsay, M., Lopez Bernal, J., White, J., Andrews, N., Campbell, C., Stowe, J.
10.1101/2021.08.27.21262422 — Posted: 2021-09-04
Optimization of single dose VSV-based COVID-19 vaccination in hamsters
O'Donnell, K. L., Clancy, C. S., Griffin, A. J., Shifflett, K., Gourdine, T., Thomas, T., Long, C. M., Furuyama, W., Marzi, A.
10.1101/2021.09.03.458735 — Posted: 2021-09-03
Discovery of highly potent pancoronavirus fusion inhibitors that also effectively inhibit COVID-19 variants from the UK and South Africa
Curreli, F., Ahmed, S., Victor, S. M. B., Drelich, A., Panda, S. S., Altieri, A., Kurkin, A., Tseng, C.-T., Hillyer, C., Debnath, A.
10.1101/2021.09.03.458877 — Posted: 2021-09-03 Discussion: Onsite
Mathematical modeling and adequate environmental sampling plans are essential for the public health assessment of COVID-19 pandemics: development of a monitoring indicator for SARS-CoV-2 in wastewater
Cluzel, N., Courbariaux, M., Wang, S., Moulin, L., Wurtzer, S., Bertrand, I., Laurent, K., Monfort, P., Obepine Consortium, , Le Guyader, S., Boni, M., Mouchel, J.-M., Marechal, V., Nuel, G., Maday, Y.
10.1101/2021.09.01.21262877 — Posted: 2021-09-03
Effectiveness of COVID-19 Vaccines Against SARS-CoV-2 Infection During a Delta Variant Epidemic Surge in Multnomah County, Oregon, July 2021
Barlow, R. S., Larson, L., Jian, K.
10.1101/2021.08.30.21262446 — Posted: 2021-09-03
Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)
Yorsaeng, R., Vichaiwattana, P., Klinfueng, S., Wongsrisang, L., Sudhinaraset, N., Vongpunsawad, S., Poovorawan, Y.
10.1101/2021.09.01.21262955 — Posted: 2021-09-03
Sars-Cov-2 antibody titer 3 months post-vaccination is affected by age, gender, smoking and vitamin D.
Parthymou, A., Habeos, E. E., Habeos, G. I., Deligakis, A., Livieratos, E., Marangos, M., Chartoumpekis, D. V.
10.1101/2021.09.01.21262913 — Posted: 2021-09-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).